Related Experiment Video

Updated: Aug 9, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Emerging antiangiogenic agents in lung cancer

David Lee1, John V Heymach

  • 1CIG Media Group, LP, Dallas, TX, USA.

Clinical Lung Cancer
|April 28, 2006
PubMed

Insights

Novel antiangiogenic agents targeting vascular endothelial growth factor (VEGF) are being developed to treat cancers like non-small-cell lung cancer (NSCLC). These agents, including receptor tyrosine kinase (TK) inhibitors and VEGF Trap, show clinical feasibility in ongoing trials.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The success of bevacizumab, an anti-vascular endothelial growth factor (VEGF) antibody, has driven research into new antiangiogenic therapies.
  • Novel agents aim to inhibit VEGF signaling through various mechanisms, including receptor tyrosine kinase (TK) inhibition and direct VEGF binding.

Purpose of the Study:

  • To review novel antiangiogenic agents developed following the success of bevacizumab.
  • To discuss agents targeting VEGF receptor TK activity and VEGF itself, including their mechanisms and clinical development status.

Main Methods:

  • Review of small-molecule receptor tyrosine kinase (TK) inhibitors (ZD6474, sorafenib, sunitinib malate, AG-013736) that inhibit VEGF receptor TK activity.
  • Description of VEGF Trap, a fusion molecule targeting VEGF with high affinity.
  • Summary of clinical trial data (Phase I/II) indicating feasibility.

Main Results:

  • Receptor TK inhibitors exhibit broad activity, inhibiting multiple receptors due to structural similarities.
  • VEGF Trap demonstrates specificity for the VEGF molecule.
  • Phase I/II trials suggest these novel antiangiogenic agents are clinically feasible.

Conclusions:

  • Ongoing Phase II/III trials are evaluating the efficacy of these novel antiangiogenic agents.
  • The development of diverse antiangiogenic strategies, including TK inhibitors and VEGF Trap, offers promising therapeutic avenues for cancers such as non-small-cell lung cancer (NSCLC).

More Related Videos

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...